Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.12
Views: 3486
Rating:

Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal

Dr Fatima Cardoso talks to ecancer about advances in the standard of care in the neo-adjuvant setting for triple negative and HER 2 breast cancer at the 2012 ESMO meeting in Vienna.

 

In HER 2 breast cancer, numerous advances have been made with trastuzumab, but further studies need to determine whether it is more effective in neo-adjuvant or adjuvant setting. Recently it was discovered that, for clinical practice, these agents can be used with anthracyclines.

 

Dr Cardoso also discusses the surgical challenges and prognostic factors involved in these breast cancer sub types.

 

Filming supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation